The Chemours Company— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$1.33B
↓-2.2% -$30Mvs FY2024 (Q4)
Gross Profit
$156M
↓-41.2% -$109Mvs FY2024 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $1.33B | $1.36B |
| COGS | $1.17B | $1.09B |
| Gross Profit | $156M | $265M |
| R&D | $27M | $26M |
| SG&A | $130M | $598M |
| D&A | $81M | $78M |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · CC · Comparing FY2025 (Q4) vs FY2024 (Q4)